ARTICLE | Financial News
Ansun raises $85M series A, plans Phase III for anti-viral
May 18, 2018 2:29 AM UTC
Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures and Joincap Investment.
An Ansun spokesperson told BioCentury the funding is expected to last through a Phase III trial of lead candidate DAS181 (Paradase, Fludase) to treat parainfluenza virus (PIV) in hospitalized, immunocompromised patients. It plans to begin the trial early next year...
BCIQ Company Profiles